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Understanding mitochondrial role in normal physiology and 
pathological conditions has proven to be of high importance as 
mitochondrial dysfunction is connected with a number of 
disorders as well as some of the most common diseases (e.g. 
diabetes or Parkinson’s disease). Modeling mitochondrial 
dysfunction has been difficult mainly due to unique features of 
mitochondrial genetics. Here we discuss some of the most 
important mouse models generated so far and lessons learned 
from them.  
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Chinese philosophy explains the basis of nature 
through yin and yang, opposing forces, interdependent 
and able to exist only in relation to each other. The story 
of the cell and mitochondria is very similar. It is a story 
about two enemies that have become friends and allies. 
On this particular day, an ancient bacteria has invaded a 
single cell organism and instead of killing it, as many 
times before, it has found shelter and decided to stay 
inside it. Why not, there was a lot of food within and it 
was protected from the hostile environment of the ancient 
world. As for the host cell, beside the fact that it has 
survived the attack, benefits have also been great. Finally 
it had a way of fighting poisonous oxygen that was 
surrounding it, not to mention all this new energy 
produced within. This random encounter that happened 
around 1-2 billion years ago to give rise to a synergically 
superior eukaryote, is described by the endosymbiotic 
theory (Margulis 1975). The bacterium is believed to 
become integrated into the recipient cell and evolved into 
an organelle, the mitochondrion. Whether the random 
encounter was an invasion, infection or an unwilling 
indigestion event, the yin - the anaerobic cell - and the 
yang - the aerobic mitochondrion - left their differences 
behind and cooperated. The story, which started almost as 
a horror movie, turned into a romantic comedy in the end 
- or did it? Does the initial invasion of the bacteria still 
continue even if it lost its ability to live independently? 
A number of different diseases and mitochondrial 
involvement in aging and age-associated disease seem to 
prove this.  
 
Mitochondrial involvement in disease 
 
Mitochondria are small organelle found in 
almost every cell of the organism. They form a very 
dynamic network within eukaryotic cell and occupy 
roughly one fifth of its total volume (McBride et al. 
2006). Mitochondria are considered to be the power 
generators of the cell, converting oxygen and nutrients 
into adenosine triphosphate (ATP), through process of 
oxidative phosphorylation. Mitochondria are unique 
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because they are the only organelles in animal cells 
containing their own DNA, mitochondrial DNA 
(mtDNA).  
Without mitochondria, higher animals would 
likely not exist because their cells would not be able to 
obtain enough energy. In fact, mitochondria enable cells 
to produce 15 times more ATP than they could otherwise. 
Mitochondrial energy production is a foundation for 
health and well-being. It is necessary for physical 
strength, stamina and consciousness (McBride et al. 
2006). Even subtle insufficiency in mitochondrial 
function can cause weakness, fatigue and cognitive 
difficulties (Graff et al. 2002). Furthermore, chemicals 
that strongly interfere with mitochondrial function are 
known to be potent poisons. 
Mitochondrial diseases are one of the most 
common inborn errors of metabolism with a frequency 
of about 1 in 5000 (Chinnery and Turnbull 2001). They 
are often called “mitochondrial encephalomyopathies” 
as it became apparent that brain and skeletal muscle are 
the most commonly affected tissues (Shapira et al. 
1977). Today, the term “mitochondrial diseases” is 
almost exclusively used to describe diseases caused by 
defects in mitochondrial oxidative phosphorylation 
(OXPHOS) and not defects in numerous other cellular 
processes within mitochondria. Even within these 
boundaries, the classification of the mitochondrial 
diseases became quite complicated, as it was shown that 
mutations in either mtDNA or nDNA genes coding for 
mitochondrial proteins lead to major and catastrophic 
diseases in humans. The first patient suffering from a 
mitochondrial disorder was described by Luft et al. 
(1962). Since then thousands of patients have been 
diagnosed with different kinds of mitochondrial 
diseases. Due to the complexity of mitochondrial 
diseases, they are usually classified by their genetic 
defect rather then clinical manifestation.  
 
Mitochondrial DNA diseases 
About 200 mtDNA point mutations and 
innumerable single large-scale partial deletions have been 
associated with human diseases, most of which affect the 
central and peripheral nervous system (Anderson et al. 
1981). Although genetically distinct, most mtDNA 
diseases share common features such as lactic acidosis, 
mosaic pattern of cells deficient in cytochrome c oxidase 
activity and massive mitochondrial proliferation in 
muscle resulting in ragged-red fibers (DiMauro et al. 
1985). Mitochondrial DNA diseases commonly have a 
delayed onset and progressive course. Mutations in 
mtDNA are divided into two groups: mtDNA point 
mutations and mtDNA rearrangements. A couple of 
unique features of mtDNA genetics and inheritance make 
it very difficult to predict the course of the disease, 
prenatal diagnosis and/or genetic counseling in everyday 
clinical practice:  
(i) mtDNA does not follow the Mendelian rules 
of inheritance. In most animals, as in humans, mtDNA is 
maternally inherited. Therefore, a mother carrying an 
mtDNA mutation can transmit it to her children, but only 
her daughters can further transmit it to the next 
generation. As each cell contains ∼10,000 copies of 
mtDNA, a pathogenic mutation could be present in all of 
them or just few of copies of the molecule. Existence of 
two or more different populations of mtDNA in a single 
cell is called heteroplasmy in contrast to homoplasmy 
where all mtDNA molecules are identical.  
(ii) Threshold effect represents the minimal 
critical level of a pathogenic mutation in mtDNA that 
should be present in the cell or tissue to have a 
deleterious effect. A certain proportion of mutant mtDNA 
must be present before reduction of OXPHOS activity is 
observed, and the threshold is lower in tissues that are 
more dependent on oxidative metabolism. It has been 
shown that there are different thresholds for different 
types of mtDNA mutations, ranging from 90 % for some 
tRNA mutations (Chomyn et al. 1992, Hanna et al. 1995) 
to 60 % for mtDNA deletions (Bourgeron et al. 1993).  
(iii) The last but not the least problem of mtDNA 
genetics is the mitotic segregation. Random distribution 
of mtDNA molecules during cell division can lead to 
increased amounts of mutant mtDNA molecules in one of 
the daughter cells. This can lead to a cell carrying low 
levels of mutated molecules giving rise to one of 
relatively high levels, which in turn will affect oxidative 
phosphorylation in that cell.  
 
Nuclear DNA mutations 
Mitochondrial diseases caused by a mutation in 
nuclear encoded genes are a very heterogeneous group. 
Not only are most of the ~80 structural proteins of the 
OXPHOS system encoded by nDNA, but all the proteins 
needed for their import from the cytoplasm and assembly 
in mitochondria are also encoded by nucleus. Defects in 
any of these proteins could lead to functionally impaired 
OXPHOS and therefore to mitochondrial disease. 
Furthermore, defects in any protein affecting stability 
and/or integrity of mtDNA could lead to the same 
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deleterious effect.  
Certain tissues such as heart, brain, and skeletal 
muscle are very dependent on the OXPHOS for energy 
production; therefore it is not surprising that these tissues 
tend to be involved mitochondrial diseases. However, this 
cannot explain the diverse manifestations of mutations 
that would be predicted to have similar effects. For 
instance; central nervous system (CNS) involvement in 
mitochondrial diseases is clinically heterogeneous, 
manifesting as epilepsy, stroke-like episodes, migraine, 
ataxia, spasticity, extrapyramidal abnormalities, 
leukoencephalopathy, bulbar dysfunction, psychiatric 
abnormalities, neuropsychological deficits, or 
hypophysial abnormalities. The mechanisms that regulate 
the tissue-specific consequence of mitochondrial disease 
are still largely unknown. In fact, the different patterns of 
energy crisis are perhaps the most puzzling dilemma in 
the field. Therefore, many attempts were made in order to 
model the mitochondrial diseases in mice.  
 
Introducing mutations into mtDNA: the 
mito-mouse and mito-PstI-mice 
 
Generation of animal models carrying mtDNA 
mutations has proven to be extremely difficult mainly 
because DNA transformation of mitochondria inside 
living cells is basically unfeasible. The introduced DNA 
must cross not one, but three membranes (the plasma 
membrane, plus two mitochondrial membranes), while 
preserving cell and organelle integrity and viability. 
Furthermore, mtDNA exists in high copy number in each 
cell, meaning that numerous transformation events are 
required to ensure introduced mtDNA to reach 
meaningful levels. These technical difficulties have given 
rise to different approaches to manipulate the mtDNA in 
experimental animals.  
 
Mito-mice 
First attempt to generate a mouse model carrying 
mutated mtDNA was accomplished by introduction of 
exogenous mitochondria carrying a large deletion into 
mouse zygotes (Inoue et al. 2000). Mitochondria carrying 
somatic mtDNA mutations from aged mouse brain 
(synaptosomes) were fused to mouse ρ0 cells (cells 
without mtDNA) to create cybrid clones. A clone stably 
expressing a single large deletion (Δmt4696) was then 
enucleated and introduced into mouse zygotes using 
electrofusion. Following the implantation of those into 
pseudopregnant females, 5 heteroplasmic founder 
females out of 111 newborn mice were bred and germline 
transmission was obtained in F0 generation. Mutant 
mtDNA accumulated in F1 - F3 progenies and caused 
mitochondrial dysfunction. The mitochondrial-transgenic 
mice obtained in this way inherited various levels  
(5-90 %) of deleted mtDNA and were named delta-
mtDNA (ΔmtDNA) mice or mito-mice. There was a 
strong correlation between pathological phenotypes and 
the level of deleted mtDNA. Mice with high levels of 
Δmt4696 presented mitochondrial disease phenotypes 
such as low body weight, lactic acidosis, systemic 
ischemia, auriculoventricular block with Wenckebach 
periodicity, hearing loss, renal failures, and male 
infertility (Inoue et al. 2000, Nakada et al. 2001, 2006). 
Early symptoms of the lactic acidosis, low body weight, 
and sperm abnormalities could be detected in mito-mice 
carrying approximately more than 75 % mtDNA. 
Surprisingly, the deleted mtDNA was transmitted through 
the maternal line to the offspring, although single 
mtDNA deletions are not usually inherited. Mito-mice 
with predominant levels of deleted mtDNA molecules 
died around seven months of age of renal failure. This 
came as a bit of surprise as renal failure is not a common 
lesion in mitochondrial diseases. Nevertheless, phenotype 
of Mito-mice mimic early-onset Pearson syndrome in 
humans that is caused by a single heteroplasmic mtDNA 
deletion and leads to anaemia, mitochondrial myopathy 
and pancreatic and renal insufficiency. 
 
Mitochondrial PstI mice 
An elegant way of inducing mtDNA depletion 
into mouse model was accomplished by expression of 
mitochondrially-targeted Restriction Endonuclease (PstI), 
specifically in skeletal muscle. Mouse mtDNA harbors 
two PstI sites, and transgenic founders had high levels of 
double-strand brakes leading to mtDNA depletion 
associated with development of mitochondrial myopathy 
(Srivastava and Moraes 2001). The founders showed a 
chimeric pattern of transgene expression and their 
residual level of wild-type mtDNA in muscle was ~ 40 % 
of controls. Beside high levels of mtDNA depletion, these 
mice carried multiple, large mtDNA deletions in muscle. 
Most of these deletions involved one of the PstI sites and 
the 3′-end of the D-loop region and were characterized by 
no or small direct repeats at the breakpoint region. This 
implies that double-strand breaks may be involved in the 
generation of multiple-deletion syndromes in humans, as 
these deletions share basically identical features. 
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Many lessons learned from Tfam-deficient 
mice  
 
Facing with challenges in direct mitochondrial 
DNA manipulations, scientists chose to take another 
approach and they have generated mutations in 
components that are needed for the mtDNA maintenance 
and/or expression. Maintenance and expression of 
mtDNA are completely dependent on nuclear genes and it 
is therefore possible to produce a global reduction of 
mtDNA expression, similar to the reduction observed in 
patients with mtDNA mutations, by disruption of nuclear 
genes.  
One of the very first attempts of mimicking 
mitochondrial dysfunction in mice was developed by 
disrupting the nuclear Tfam gene, which encodes a 
transcriptional activator that is imported to mitochondria 
(Larsson et al. 1996, 1998). The TFAM protein 
specifically binds mtDNA promoters and activates 
transcription (Larsson et al. 1996). TFAM has the ability 
to bend and unwind DNA and may activate transcription 
by facilitating binding of mitochondrial RNA polymerase 
and other factors to the mtDNA promoters. Mitochondrial 
transcription is not only necessary for gene expression 
but also for mtDNA replication by providing the RNA 
primers necessary for initiation of mtDNA replication by 
mitochondrial DNA polymerase. Transcription is thus a 
prerequisite for mtDNA replication. Furthermore, TFAM 
is a very abundant protein, fully coating mtDNA, 
therefore it plays important role in mtDNA maintenance 
in mammals (Larsson et al. 1996). Tfam is absolutely 
required for mtDNA maintenance in vivo, and 
homozygous germ line Tfam knockouts lack mtDNA and 
die during embryogenesis (Larsson et al. 1998). 
Characterization of tissue-specific Tfam knockouts has 
demonstrated that TFAM deficiency leads to mtDNA 
depletion, reduction in levels of mitochondrial transcripts, 
and severe respiratory chain deficiency (Wang et al. 
1999, Silva et al. 2000, Sorensen et al. 2001, Ekstrand et 
al. 2007). Furthermore, selective disruption of Tfam in 
different tissues has shown that diverse cell types vary 
considerably in their tolerance to reduced mtDNA levels. 
Interestingly, the phenotype of tissue-specific Tfam 
knockouts faithfully reproduces pathology found in 
humans with mtDNA disorders. It is thus likely that 
impaired mtDNA expression is a key pathogenesis 
feature of mtDNA disorders and that the distribution of 
mtDNA and, as a consequence, the distribution of the 
respiratory chain deficiency is the main determinant of 
the phenotype.  
Selective Tfam disruption in heart and skeletal 
muscle leads to development of a mosaic cardiac-specific 
progressive respiratory chain deficiency, dilated 
cardiomyopathy, atrioventricular heart conduction blocks. 
These animals die very early, at around 2-4 weeks of age, 
providing genetic evidence that the respiratory chain is 
critical for normal heart function. Furthermore, these 
animals reproduce biochemical, morphological and 
physiological features of the dilated cardiomyopathy of 
Kearns-Sayre syndrome (Schon et al. 1995, Wang et al. 
1999).  
It has been estimated that around 0.5-1 % of all 
cases of diabetes mellitus are caused by mtDNA 
mutations. A mouse model engineered to have Tfam 
deficiency specifically in pancreatic beta-cells faithfully 
mimics features of mitochondrial diabetes in humans 
(Silva et al. 2000). The mice developed diabetes from the 
age of 5 weeks and displayed severe mtDNA depletion, 
deficient oxidative phosphorylation and abnormal 
appearing mitochondria in islets at the ages of 7-9 weeks. 
Physiological studies revealed reduced hyperpolarization 
of the mitochondrial membrane potential, impaired Ca2+-
signalling and lowered insulin release in response to 
glucose stimulation. This animal model provides genetic 
evidence for a critical role of the respiratory chain in 
insulin secretion. 
Mitochondrial late-onset neurodegeneration 
(MILON) mice were generated after postnatal deletion of 
Tfam gene in forebrain neurons (Sorensen et al. 2001). 
MILON mice appeared perfectly normal and showed no 
abnormalities until the age of 5-6 months. Following this 
time period, their physical condition deteriorates pretty 
rapidly and death occurs within 1-2 weeks. MILON mice 
displayed a progressive, marked neuronal cell loss, 
degeneration, severe disruption of cortical organization 
and axonal degeneration in neocortex and hippocampus. 
This was accompanied by a significant reduction in 
mtDNA copy number and mtRNA levels in neocortex of 
MILON mice. The importance of MILON mice comes 
from the fact that it successfully mimics the late-onset 
and progressive nature of human neurodegenerative 
diseases.  
Genetic evidence for the role of mitochondrial 
dysfunction in development of parkinsonian phenotype 
came from the MitoPark mouse. This mouse model have 
a midbrain, dopamine (DA) neuron specific Tfam 
deficiency and recapitulate several features of Parkinson's 
Disease (PD) in humans such as adult-onset degeneration 
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of nigrostriatal dopamine circuitry; motor deficits that are 
ameliorated by L-DOPA administration; progressive 
course of phenotypic manifestations and 
neurodegeneration; and altered response to L-DOPA 
treatment dependent on disease stage. The mice appear 
normal until adolescence, followed by development of 
PD-like motor problems and clinical features similar to 
PD patients who respond well to L-DOPA treatment 
(Ekstrand et al. 2007). Despite showing signs of motor 
deficits at 14 to 20 weeks of age, the mice survive until 
45 weeks at which point they need to be sacrificed due to 
their poor general condition. Maybe the most important 
feature of MitoPark mice was that they fully mimic 
delayed onset and progressive course of symptoms of PD, 
something that was very difficult to reproduce with other 
animal models.  
 
Mouse models mimicking neurodegenerative 
diseases  
 
The lack of mouse models presents a major 
obstacle to study the effect of mitochondrial dysfunction 
in postmitotic tissues, such as the brain. Over the years 
attempts were made to generate models that will replicate 
neurodegenerative diseases such as Leigh syndrome, 
ethylmalonic encephalopathy, mitochondrial 
neurogastrointestinal encephalomyopathy and 
encephalomyelopathy. We will discuss just a few of 
them.  
 
Surf1 deficient mice 
Leigh syndrome (LS) or subacute necrotizing 
encephalomyelopathy, is an early-onset progressive 
neurodegenerative disorder characterized by predominant 
involvement of the central nervous system (CNS) (Leigh 
1951). Usually affects infants under the age of two and 
has a very poor prognosis, as most of the patients die 
within few years. Mutations in both nuclear and 
mitochondrial genes have been identified in LS patients. 
Mutations in the nuclear Surf1 gene, coding for a putative 
complex IV (cytochrome c oxidase (COX)) assembly 
factor are one of the main cause of LS (Tiranti et al. 
1998, 1999). In these patients, SURF1p mutations or 
depletions cause a reduction in the fully assembled COX 
(Tiranti et al. 1999). Surprisingly, Surf1 deficient mice 
displayed mild reduction of COX activity in all tissues, 
with no Leigh’s syndrome lesions in the CNS. The Surf1 
deficient mice have a slightly smaller size at birth that is 
corrected later in life and show only mild differences in 
motor skills and blood lactate levels, comparing to 
littermates (Dell'agnello et al. 2007). The mild phenotype 
could be explained by the fact that SURF1 is not a 
fundamental COX assembly factor in mice as it is in 
humans. Unexpectedly, these animals displayed broad 
protection from in vivo neurodegeneration induced by 
exposure to high doses of kainic acid. It was suggested 
that these findings are associated with reduced 
mitochondrial uptake of calcium ions and cellular 
calcium homeostasis. Maybe the most striking result of 
this unusual model system was the prolonged lifespan 
that is observed in those animals. This is in great contrast 
with the severe and fatal encephalomyelopathy in humans 
with Surf1 mutations. However, it goes very well with 
the findings in both roundworm, Caenorhabditis elegans 
and fruit fly, Drosophila melanogaster, that mild 
mitochondrial dysfunction prolongs lifespan (Dillin et al. 
2002, Rea et al. 2007, Copeland et al. 2009). 
 
TK2 deficient mice 
Thymidine kinase 2 (TK2) is an enzyme that 
phosphorylates pyrimidine nucleosides inside 
mitochondria. Mutations in TK2 cause the impairment in 
mitochondrial nucleotide salvage pathway and leads to 
mtDNA depletion syndrome (MDS), an autosomal 
recessive disorder of infancy or childhood characterized 
by decreased mitochondrial DNA copy number in 
affected tissues (Mancuso et al. 2002). To further 
elucidate the tissue-specific effects of TK2 deficiency, 
two different TK2 mouse models were generated: the 
knock-out (TK2-deficient mice) (Zhou et al. 2008) and 
the knock-in mice (Akman et al. 2008). A week after 
birth TK2-deficient mice exhibited failure to thrive, 
severe growth retardation, lipodystrophy, and 
hypothermia resulting in a very early death (Zhou et al. 
2008). These changes were mirrored by progressive 
mtDNA depletion in multiple organs including skeletal 
muscle, heart, brain, liver, and spleen. Although TK2 
deficiency caused severe mtDNA depletion, the 
remaining copies were intact and showed no increase in 
number of mtDNA mutations or deletions. 
Approximately at the same time a TK2 mouse model 
carrying the H126N mutation (homolog to human H121N 
pathogenic mutation) was generated (Akman et al. 2008). 
These mice showed severe and rapidly progressive 
encephalomyelopathy after 10 days and died between 
ages 2 and 3 weeks. Further investigation revealed that 
TK2 deficiency in these animals leads to unbalanced 
dNTP pools and general mtDNA depletion. However, in 
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contrast to the widespread defects of mtDNA, only brain 
showed decreased activities of respiratory chain enzymes. 
It seems that in most tissues, but brain, levels of mtDNA-
encoded polypeptides were maintained at levels similar to 
controls indicating transcriptional or translational 
compensation for the mtDNA defect. Transcriptional 
compensation for partial mtDNA depletion has been 
observed in skeletal muscle of patients with TK2 
mutations (Vila et al. 2003).  
 
Deletor mice 
Twinkle is a nuclear-encoded mitochondrial 
helicase, which, together with mitochondrial DNA 
polymerase (POLG) and mitochondrial single-stranded 
DNA-binding protein forms minimal mitochondrial 
replisome (Korhonen et al. 2004). In humans, dominant 
mutations in Twinkle are cause of adult-onset progressive 
external ophthalmoplegia (PEO), which is associated with 
multiple mtDNA deletions (Spelbrink et al. 2001). 
Transgenic mice expressing a mutant murine Twinkle 
carrying a duplication-mutation (dup353–365) 
homologous to the one found in PEO patients, very 
accurately replicates human disease. These ‘Deletor’ 
mice (due to multiple mtDNA deletion accumulation in 
their tissues) show progressive respiratory deficiency and 
chronic late-onset mitochondrial disease in skeletal 
muscle starting at around one year of age. Respiratory 
dysfunction is also apparent in distinct neuronal 
populations such as cerebellar Purkinje cells and 
hippocampal neurons. Although Deletor-mice accumulate 
mtDNA deletions and displays clear signs of adult-onset 
mitochondrial myopathy and neurodegeneration, the 
lifespan was not affected. 
 
Mitochondrial involvement in aging: mtDNA 
mutator mice 
 
The involvement of mitochondrial DNA 
(mtDNA) in the aging process mainly stems from their 
location, in close proximity to the mitochondrial 
respiratory chain, which is the main source of reactive 
oxygen species (ROS) generation and therefore helps 
explain their susceptibility to oxidative damage. This 
vulnerability of mtDNA has led to the suggestion that the 
accumulation of somatic mtDNA mutations might play 
an important role in the aging process by producing cells 
with a decreased oxidative capacity (Harman 1972). We 
developed a model that provided evidence in direct 
support for the involvement of mitochondria in the 
process of aging (Trifunovic et al. 2004). We created 
homozygous knock-in mice expressing a error prone form 
of the nuclear-encoded mitochondrial DNA polymerase 
(POLG). As the proofreading in the knock-in mice is 
efficiently prevented, these mice develop the mtDNA 
mutator phenotype (mtDNA mutator mice) with a three to 
fivefold increase in the levels of point mutations. The 
mtDNA mutator mice display a completely normal 
phenotype at birth and in early adolescence until the age 
of ~25 weeks when first signs of kyphosis and hair loss 
were noticeable. As the animals got older the kyphosis 
became marked, varying degrees of alopecia appeared 
and the animals became progressively leaner and less 
active. The median life span of the mtDNA mutator mice 
was approximately 48 weeks and all of them died or 
became moribund before the age of 61 weeks. 
Measurements of whole body bone mineral density 
(BMD) showed a clear reduction with increasing age, 
consistent with the clinical features of osteoporosis, 
commonly detected in aging humans (Kalu 1995). 
MtDNA mutator hearts shoved signs of dilated 
cardiomyopathy with marked cardiac hypertrophy and 
mosaic distribution of COX-deficient cardiomyocytes 
(Trifunovic et al. 2004). Furthermore, a profound 
reduction in fertility of mtDNA-mutator mice of both 
sexes was detected. MtDNA mutator females usually 
produced 1 or 2 liters of normal size, but they never 
became pregnant again after the age of 25 weeks despite 
being continuously exposed to males for several months. 
Studies on the auditory system pathology of mutator mice 
and humans with presbyacusis (age-related hearing loss) 
showed striking similarities (Niu et al. 2007). Apoptotic 
cell loss in the spiral ganglion and progressive 
degeneration of neurons in the cochlear nucleus were the 
most probable cause of the presbyacusis-like phenotype 
observed in aging mtDNA mutator mice.  
 Confirmation of our results came from another, 
independently developed mtDNA mutator mice (Kujoth 
et al. 2005). Surprisingly, both models showed that 
increased levels of mtDNA mutations were not associated 
with increased ROS production or increased oxidative 
stress in mtDNA mutator mice (Kujoth et al. 2005, 
Trifunovic et al. 2005). In agreement with this, we 
observed normal sensitivity to oxidative stress-induced 
cell death in mouse embryonic fibroblasts from mtDNA 
mutator mice, despite the presence of a severe 
respiratory-chain dysfunction (Trifunovic et al. 2005).  
The main consequence the mitochondrial proof 
reading deficiency in mtDNA mutator mice is the 
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massive, progressive, random accumulation of mtDNA 
mutations during the course of mitochondrial biogenesis 
(Trifunovic et al. 2004). MtDNA mutator mice 
accumulate mutations in a linear fashion, suggesting no 
involvement of a vicious circle predicted by the 
mitochondrial theory of aging (Trifunovic et al. 2005). 
We believe that the premature aging phenotypes in 
mtDNA mutator mice are not generated by massively 
increased oxidative stress accompanied by exponential 
accumulation of mtDNA mutations, but that respiratory-
chain dysfunction per se is the primary inducer of 
premature aging (Trifunovic et al. 2005). However, it is 
still possible that mutation load might be an 
underestimate since cells with the highest levels of 
deleterious mutations may be lost due to cell death and/or 
replicative disadvantage. 
Due to constant abortive replication, 
demonstrated by the presence of linear deleted mtDNA 
molecules, mtDNA mutator mice display ~25 % decrease 
in the levels of full-length mtDNA (Trifunovic et al. 
2004). Although reduced copy number of full-length 
mtDNA does not affect overall mtDNA expression we 
cannot completely exclude a possibility that described 
reduction in the levels of full-length mtDNA could 
contribute to the phenotypes (Edgar et al. 2009).  
Our latest results strongly argue that the 
observed phenotypes are a direct consequence of the 
accumulation of mtDNA point mutations (Edgar et al. 
2009). We believe that even though mtDNA mutator 
mice randomly accumulate point mutations, these 
mutations have deleterious impact primarily on the 
protein-coding genes. This is in agreement with our 
recent finding of strong purifying selection against 
mutations in the protein-coding genes during germline 
transmission of mutated mtDNA in the mouse (Stewart et 




Animal models are invaluable tools for in depth 
study of human pathologies in vivo. Development of 
models for mitochondrial diseases has proved to be very 
challenging, but a great deal of progress has been made in 
the last decade. The existing mouse models will still be 
very useful for studies of pathogenesis and, in some 
cases, for testing potential treatments for mitochondrial 
disorders. To further elucidate the role of mtDNA 
maintenance and expression mechanisms and their effect 
on human pathologies and disease, more models carrying 
patient mutations would need to be generated. 
Furthermore, mitochondrial dysfunction is more and 
more associated with common diseases such as 
neurodegeneration and metabolic syndrome, as well as 
aging, which emphasizes the role mouse models in 
understanding the role of mitochondrial dysfunction in 
common pathologies. 
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